

NEWSLETTER May – June 2019

CEO's greetings

The EURAPS 2019 meeting brought together many European experts in the treatment of lymphedema. We took the opportunity of arranging a get-together with several key opinion leaders, to share our progress in the development of Lymfactin® and to discuss possible next steps. It was very rewarding to be received with such enthusiasm by such experts. Big thanks to all participants!

Greetings also from Europe's annual biotech investor meeting, BioEquity, this time in Barcelona. One topic of discussion was how Europe's biotech hubs can compete against Boston and San Francisco. For instance, do PhDs dare leave the academia for high-risk startups if the job market is not that broad? Yes! Is what I would say based on fresh experience. We've received good applications for our new Senior Scientist position!

CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE study is actively recruiting patients in Sweden and Finland. See [Lymfactin web site](#) for more information.
- **Parkinson's disease:** Phase 1–2 study with CDNF ongoing, not actively recruiting new patients.
- **Breast Cancer Associated Lymphedema:** Phase 1 study in long-term follow-up, not actively recruiting patients.

PLANNED ACTIVITIES

- **Neurotrophic Factors meeting**, 21-22 Aug 2019 in Grand Rapids, USA
- **Interim report on Jan-Jun 2019:** 28 Aug 2019
- **Aktiespararna**, 10 Sep 2019 in Stockholm: Company presentation to Swedish investors
- **Nordic Life Sciences Days**, 11-12 Sep 2019 in Malmö, Sweden
- **Life Science Investor Meetings**, 18 Sep 2019 in Copenhagen: Company presentation to investors

Herantis of the month



Lymfactin® Project Manager **Satu** representing Herantis at the EURAPS meeting

Keep up-to-date on Herantis:



Contact us



@Herantis Pharma



Subscribe

We are hiring!

We have opened a new position of **Senior Scientist, in vivo Pharmacology**, to support our preclinical development programs, with focus on CNS diseases.

Please refer to this recruitment ad for details and for how to apply: [Senior Scientist, in vivo pharmacology](#)

Topics of interest

Our Lymfactin® is a gene therapy. Therefore we have followed with interest the recent progress in the field of gene therapy. After decades of hype, gene therapy is finally becoming routine clinical practice as evidenced by several recent market approvals. Not surprisingly, the pricing of gene therapy drugs has become a novel topic of discussion, also touched upon in [our recent blogging](#).

Herantis in the news

Success Story article published by the European Commission covering Herantis' clinical study in Parkinson's disease, based on an interview with Herantis' CEO **Pekka Simula**, and Professor **Mart Saarna** of the University of Helsinki: [Novel drug delivered direct to brain may halt Parkinson's](#)